The use of aromatase inhibitors for breast cancer treatment and osteoporosis <b>[Abstract in English]</b>

Authors

  • Lina B. Cassol
  • Bernardo Garicochea

Abstract

Objectives: Recently, aromatase inhibitors have become an alternative to tamoxifen for hormonal therapy of postmenopausal women with hormone receptor-positive breast cancer. Aromatase inhibitors cause usually few side effects, but there are questions about their long term impact over bone loss and osteoporosis development. This review describes the relationship between estrogens and bone metabolism; pharmacologic and clinical data about main aromatase inhibitors and their impact on osteoporosis development and diagnostic, preventive and therapeutic methods for osteoporosis which must be employed in breast cancer patients receiving aromatase inhibitors.
Data search: This review article was based in papers published last five years selected through a Medline search and in selected articles’ references.
Data synthesis: The treatment with aromatase inhibitors is related to an increased incidence of osteoporosis and fractures.
Conclusion: Diagnostic, preventive and therapeutic methods for osteoporosis must be early employed in breast cancer patients receiving aromatase inhibitors.
KEY WORDS: BREAST NEOPLASMS; AROMATASE/ antagonists & inhibitors; OSTEOPOROSIS.

Downloads

Download data is not yet available.

Downloads

Published

2006-10-23

How to Cite

Cassol, L. B., & Garicochea, B. (2006). The use of aromatase inhibitors for breast cancer treatment and osteoporosis <b>[Abstract in English]</b>. Scientia Medica, 15(4). Retrieved from https://revistaseletronicas.pucrs.br/ojs/index.php/scientiamedica/article/view/1581

Issue

Vol. 15 No. 4 (2005)

Section

Review Articles

License

Copyright

The submission of originals to Scientia Medica implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite Scientia Medica as the site of original publication.

Creative Commons License

Except where otherwise specified, material published in this journal is licensed under a Creative Commons Attribution 4.0 International license, which allows unrestricted use, distribution and reproduction in any medium, provided the original publication is correctly cited.